InvestorsHub Logo
Followers 91
Posts 11332
Boards Moderated 0
Alias Born 06/06/2014

Re: None

Friday, 11/06/2015 6:23:26 PM

Friday, November 06, 2015 6:23:26 PM

Post# of 461747
The market is looking for results on Saturday that, if repeated in a broader phase 3, would prospectively be adequate for FDA approval. My opinion is that is a relatively low bar given that 2-73 is so well tolerated and that any proven marginal cognitive improvement in AD indications over current standard of care is rare. A low bar that hopefully we will pass.

I hope to see the final Part A results are consistent with the July interim results. That would be "great." And sustained benefit in the interim Part B would be "excellent." I'll voice my grade here tomorrow in case anyone is interested and would love to hear others opinions likewise.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News